FindMyKOL
Clinical trialNCT04720664TerminatedPhase 2Interventional

Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer

SponsorGeorgetown UniversityEnrollment11Breast CancerHormone Receptor Positive Breast CarcinomaMetastatic Breast Cancer
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a phase II single arm, open-label study of SM-88 used with methoxsalen, phenytoin, and sirolimus (MPS) in metastatic HR+/HER2- breast cancer. It is designed to determine efficacy, defined as the objective response rate (ORR) of this investigational treatment. It is hypothesized that SM-88 used with MPS will lead to significant anti-tumor responses with acceptable toxicities in patients with metastatic HR+/HER2- breast cancer.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Medstar Georgetown University Hospital, Lombardi Comprehensive Cancer Center

    Washington D.C., District of Columbia, United States

  • Medstar Washington Hospital Center

    Washington D.C., District of Columbia, United States

  • Medstar Franklin Square Medical Center

    Baltimore, Maryland, United States

  • Medstar Good Samaritan Hospital

    Baltimore, Maryland, United States

  • Hackensack University Medical Center

    Hackensack, New Jersey, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

SM-88
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
22 Sept 2021
Primary completion
10 Feb 2023
Completion
10 Feb 2023
Last update posted
28 Aug 2023
Registered enrollment
11
Registry id
NCT04720664

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 11 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.